Stockscreener 앱 받기
40.41
0.79%
-0.31
전일 마감가:
$40.72
열려 있는:
$41.24
하루 거래량:
670.61K
Relative Volume:
0.44
시가총액:
$7.71B
수익:
$29.52M
순이익/손실:
$-567.06M
주가수익비율:
-11.04
EPS:
-3.66
순현금흐름:
$-551.11M
1주 성능:
-2.58%
1개월 성능:
+28.99%
6개월 성능:
-28.81%
1년 성능:
+0.50%
1일 변동 폭
$40.05
$41.24
1주일 범위
$39.20
$41.80
52주 변동 폭
$29.17
$62.40
Revolution Medicines Inc Stock (RVMD) Company Profile
명칭
Revolution Medicines Inc
전화
415-766-3638
주소
700 SAGINAW DR, REDWOOD CITY, CA
RVMD을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RVMD
Revolution Medicines Inc
|
40.39 | 7.71B | 29.52M | -567.06M | -551.11M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.18 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.28 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.27 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.18 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.48 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Revolution Medicines Inc Stock (RVMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-16 | 재확인 | Needham | Buy |
| 2024-07-12 | 개시 | Barclays | Overweight |
| 2024-07-08 | 개시 | Jefferies | Buy |
| 2024-04-12 | 재확인 | Needham | Buy |
| 2024-04-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-11 | 개시 | Piper Sandler | Overweight |
| 2024-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2024-01-04 | 개시 | Wedbush | Outperform |
| 2023-11-16 | 개시 | Raymond James | Outperform |
| 2023-02-28 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2022-12-14 | 개시 | Needham | Buy |
| 2022-10-21 | 개시 | Oppenheimer | Outperform |
| 2022-05-20 | 개시 | BofA Securities | Neutral |
| 2022-03-01 | 업그레이드 | Stifel | Hold → Buy |
| 2021-09-23 | 개시 | Stifel | Hold |
| 2021-08-12 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-05-18 | 개시 | Goldman | Buy |
| 2020-05-21 | 개시 | H.C. Wainwright | Buy |
| 2020-03-09 | 개시 | Cowen | Outperform |
| 2020-03-09 | 개시 | Guggenheim | Buy |
| 2020-03-09 | 개시 | JP Morgan | Neutral |
모두보기
Revolution Medicines Inc 주식(RVMD)의 최신 뉴스
(RVMD) Investment Report - news.stocktradersdaily.com
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Regeneron (REGN) - The Globe and Mail
Revolution Medicines Inc [RVMD] Records 50-Day SMA of $37.82 - knoxdaily.com
Revolution Medicines Sets Date for Q1 2025 Financial Results: Key Updates Expected from RAS Cancer Pipeline - Stock Titan
Revolution Medicines, Inc. to Report Q1 2025 Financial Results on May 7, 2025 - Nasdaq
Revolution Medicines to Report Financial Results for First Quarter 2025 After Market Close on May 7, 2025 - GlobeNewswire
Why Is Cancer Drug Developer Revolution Medicines Stock Trading Higher On Monday? - AOL.com
Revolution Medicines’ (RVMD) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Revolution Medicines (RVMD) Reports Promising Data for Zoldonras - GuruFocus
A Guide To The Risks Of Investing In Revolution Medicines Inc (RVMD) - knoxdaily.com
Revolution Medicines Shares Rise on 'Encouraging' Phase 1 Lung Cancer Trial Data - marketscreener.com
Revolution’s Next KRAS Drug Shows Promise In NSCLC - insights.citeline.com
AACR 2025: Revolution has early stage KRAS success in NSCLC - BioWorld MedTech
Perhaps timely catching Revolution Medicines Inc (RVMD) would be a good idea - Sete News
Revolution Medicines Presents Initial Data from Zoldonrasib (RMC - GuruFocus
Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting | RVMD Stock News - GuruFocus
Revolution Medicines Reports Promising Clinical Data for Zoldonrasib in KRAS G12D Mutant Non-Small Cell Lung Cancer at AACR Annual Meeting - Nasdaq
Revolution Medicines Presents Initial Data from Zoldonrasib (RMC-9805) Study in Patients with KRAS G12D Mutant Non-Small Cell Lung Cancer at the 2025 AACR Annual Meeting - GlobeNewswire
Revolutionary KRAS Cancer Drug Achieves 61% Response Rate in Lung Cancer PatientsKey Trial Data Released - Stock Titan
Russell Investments Group Ltd. Increases Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD) - Defense World
Revolution Medicines Inc (RVMD) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
RVMD Stock Sees Surge of Approximately 3.08% in Last Five Days - knoxdaily.com
This trade activity should not be overlooked: Revolution Medicines Inc (RVMD) - Sete News
Revolution Medicines Inc [RVMD] stock was sold by Cislini Jeff at the price of US$79008.0 - knoxdaily.com
Revolution Medicines to Participate in April 2025 Investor Conferences - GlobeNewswire
(RVMD) Trading Signals - news.stocktradersdaily.com
Revolution Medicines at Stifel Forum: RAS-Driven Cancer Insights By Investing.com - Investing.com Canada
Revolution Medicines: Overpriced RAS-Addicted Cancers Maven (NASDAQ:RVMD) - Seeking Alpha
Revolution Medicines stock hits 52-week low at $30.02 - Investing.com Australia
Revolution Medicines at Needham Conference: Progress in Cancer Treatment - Investing.com Australia
Revolution Medicines at Needham Conference: Progress in Cancer Treatment By Investing.com - Investing.com Canada
Revolution Medicines stock hits 52-week low at $30.02 By Investing.com - Investing.com India
Revolution Medicines Inc [RVMD] Records 50-Day SMA of $39.97 - knoxdaily.com
When the Price of (RVMD) Talks, People Listen - news.stocktradersdaily.com
Revolution Medicines (NASDAQ:RVMD) Price Target Lowered to $64.00 at Stifel Nicolaus - Defense World
Revolution Medicines to Deliver Multiple Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times
Revolution Medicines to Deliver Multiple Presentations at - GlobeNewswire
Groundbreaking Lung Cancer Drug Data Revealed: Revolution Medicines' First Clinical Results - Stock Titan
Revolution Medicines (RVMD): The Best Debt Free Mid Cap Stock to Buy Now - MSN
Revolution Medicines Brings Groundbreaking RAS Cancer Research to Major Healthcare Forums - Stock Titan
Is Revolution Medicines (RVMD) the Best Mid Cap Biotech Stock to Buy? - Insider Monkey
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Revolution Medicines general counsel Jeff Cislini sells $79,008 in stock By Investing.com - Investing.com South Africa
Revolution Medicines general counsel Jeff Cislini sells $79,008 in stock - Investing.com
Revolution Medicines executive sells shares worth $128,598 By Investing.com - Investing.com Australia
Revolution Medicines’ general counsel sells $56,920 in stock By Investing.com - Investing.com Australia
Revolution Medicines CEO Mark Goldsmith sells $458,255 in stock By Investing.com - Investing.com Australia
Revolution Medicines CFO Jack Anders sells $72,771 in stock By Investing.com - Investing.com Canada
Revolution Medicines’ general counsel sells $56,920 in stock - Investing.com India
Revolution Medicines CFO Jack Anders sells $72,771 in stock - Investing.com
Revolution Medicines Executives Sell Shares - TradingView
Revolution Medicines Inc (RVMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
0.30%
자본화:
|
볼륨(24시간):